EPIOMIC EPIDEMIOLOGY SERIES: WILSON’S DISEASE FORECAST IN 28 MAJOR MARKETS 2018–2028
- September 2018 •
- 100 pages •
- Report ID: 5564030 •
- Format: PDF
Wilson’s disease, also known as progressive lenticular degeneration, is a genetic disorder inherited in an autosomal recessive manner. It is caused by mutations in a gene coding for a copper-transporting protein with a key role in copper metabolism. Reduced activity of the protein leads to copper accumulation in the body which results in various hepatic, osseous, neurological and psychiatric manifestations. Although the genotype–phenotype correlation is still to be elucidated, therapies that are currently available permit patients to live fairly normal lives. However, hepatic and neurological damage sustained prior to the commencement of therapy can be irreversible.
This report provides the current prevalent population for Wilson’s disease across 28 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Belgium, Norway, Sweden, Denmark, Finland, Austria, Switzerland, Ireland, Bulgaria, Russia, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, Wilson’s disease patients grouped by genetic features, various symptoms and treatments have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities of Wilson’s disease include:
•Hepatitis and liver cirrhosis
•Back pain and stiffness
•Osteoporosis and frequent bone fractures
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
•Ability to quantify patient populations in global Wilson’s disease market to target the development of future products, pricing strategies and launch plans.
•Further insight into the prevalence of the subdivided types of Wilson’s disease and identification of patient segments with high potential.
•Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
•Identification of Wilson’s disease patient sub-populations that require treatment.
•Better understanding of the specific markets that have the largest number of Wilson’s disease patients.